EFFECT OF FAMOTIDINE ON THE PHARMACOKINETICS OF APIXABAN, AN ORAL DIRECT FACTOR Xa INHIBITOR, IN HEALTHY SUBJECTS.

被引：0
|
作者：
Uprett, Vijay V. [1 ]
Song, Yan [1 ]
Wang, Jessie [1 ]
Farmer, Mathew [1 ]
Pursley, Janica M. [1 ]
Li, Tong [1 ]
Frost, Charles E. [1 ]
LaCreta, Frank P. [1 ]
机构：
[1] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2009年 / 49卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
117
引用
收藏
页码：1117 / 1117
页数：1
相关论文
共 50 条
  • [31] Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits
    Donglu Zhang
    Kan He
    Nirmala Raghavan
    Lifei Wang
    Earl J. Crain
    Bing He
    Baomin Xin
    Joseph M. Luettgen
    Pancras C. Wong
    Journal of Thrombosis and Thrombolysis, 2010, 29 : 70 - 80
  • [32] Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits
    Zhang, Donglu
    He, Kan
    Raghavan, Nirmala
    Wang, Lifei
    Crain, Earl J.
    He, Bing
    Xin, Baomin
    Luettgen, Joseph M.
    Wong, Pancras C.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2010, 29 (01) : 70 - 80
  • [33] Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro
    Jiang, Xiaosui
    Crain, Earl J.
    Luettgen, Joseph M.
    Schumacher, William A.
    Wong, Pancras C.
    THROMBOSIS AND HAEMOSTASIS, 2009, 101 (04) : 780 - 782
  • [34] Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro
    Jiang, Xiaosui
    Crain, Earl J.
    Schumacher, William A.
    Wong, Pancras C.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (06) : E137 - E137
  • [35] Effect of the Direct Factor Xa Inhibitor Apixaban in Rat Models of Thrombosis and Hemostasis
    Schumacher, William A.
    Bostwick, Jeffrey S.
    Stewart, Anne B.
    Steinbacher, Thomas E.
    Xin, Baomin
    Wong, Pancras C.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2010, 55 (06) : 609 - 616
  • [36] Co-administration of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - and clopidogrel in healthy subjects
    Kubitza, D.
    Becka, M.
    Mueck, W.
    Zuehlsdorf, M.
    EUROPEAN HEART JOURNAL, 2007, 28 : 189 - 189
  • [37] Comparison of the pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor, in patients with nonvalvular atrial fibrillation and elderly healthy subjects.
    Eriksson, UG
    Wollbratt, M
    Wolzt, M
    Svensson, M
    Grind, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P95 - P95
  • [38] EFFECT OF APIXABAN, AN ORAL, DIRECT AND SELECTIVE FACTOR XA INHIBITOR ON INFLAMMATORY BIOMARKERS FOLLOWING ACUTE CORONARY SYNDROME
    Becker, Richard C.
    Lin, Annie
    Yang, Hongqiu
    Barrett, Yuchen
    Mohan, Puneet
    Wang, Jessie
    Alexander, John
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E1039 - E1039
  • [39] Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome
    Becker, Richard C.
    Alexander, John H.
    Newby, L. Kristin
    Yang, Hongqiu
    Barrett, Yuchen
    Mohan, Puneet
    Wang, Jessie
    Harrington, Robert A.
    Wallentin, Lars C.
    THROMBOSIS AND HAEMOSTASIS, 2010, 104 (05) : 976 - 983
  • [40] Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects
    Kubitza, D
    Becka, M
    Wensing, G
    Voith, B
    Zuehlsdorf, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (12) : 873 - 880
12345